{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/outcome-based-agreements-europe#webpage",
"url": "https://www.fortrea.com/insights/outcome-based-agreements-europe",
"name": "Outcome-based agreements in Europe",
"description": "Explore this Fortrea Info Sheet examining the evolving role of Outcome-Based Agreements (OBAs) and Managed Entry Agreements (MEAs) across Europe as healthcare systems increasingly adopt value-based approaches to reimbursement and patient access. The resource explores how innovative reimbursement models are being used to address uncertainty surrounding the clinical effectiveness, long-term outcomes, and budget impact of advanced therapies, including oncology treatments, rare disease therapies, and advanced therapy medicinal products (ATMPs). It outlines the key types of managed entry agreements, including financial-based agreements and health outcomes-based schemes that link reimbursement to predefined clinical outcomes and real-world performance measures. The infosheet reviews the current European landscape, highlighting how countries such as Italy, France, Germany, Spain, Sweden, Poland, Belgium, Denmark, Scotland, England, and the Netherlands are implementing outcome-based reimbursement approaches through national health technology assessment (HTA) and payer frameworks. It also examines the critical success factors for implementation, including robust real-world evidence generation, integrated healthcare data infrastructure, clearly defined outcome measures, stakeholder collaboration, legal and regulatory alignment, and transparent governance models. In addition, the resource addresses key operational challenges such as data collection complexity, administrative burden, outcomes measurement, reporting requirements, and confidentiality considerations. Looking ahead, the infosheet discusses how outcome-based agreements are expected to expand beyond oncology and rare diseases into broader therapeutic areas, supporting sustainable healthcare financing, improved patient access, and evidence-driven reimbursement decisions. Through its focus on market access, value demonstration, payer engagement, and real-world evidence, this resource provides valuable insights into the future of outcome-based healthcare and reimbursement innovation across Europe."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Outcome-based agreements in Europe",
"item": "https://www.fortrea.com/insights/outcome-based-agreements-europe"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/outcome-based-agreements-europe#infosheet",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/outcome-based-agreements-europe#webpage"
},
"headline": "Outcome-Based Agreements in Europe: Opportunities, Challenges, and Future Directions | Fortrea Info Sheet",
"description": "Explore this Fortrea Info Sheet examining the evolving role of Outcome-Based Agreements (OBAs) and Managed Entry Agreements (MEAs) across Europe as healthcare systems increasingly adopt value-based approaches to reimbursement and patient access. The resource explores how innovative reimbursement models are being used to address uncertainty surrounding the clinical effectiveness, long-term outcomes, and budget impact of advanced therapies, including oncology treatments, rare disease therapies, and advanced therapy medicinal products (ATMPs). It outlines the key types of managed entry agreements, including financial-based agreements and health outcomes-based schemes that link reimbursement to predefined clinical outcomes and real-world performance measures. The infosheet reviews the current European landscape, highlighting how countries such as Italy, France, Germany, Spain, Sweden, Poland, Belgium, Denmark, Scotland, England, and the Netherlands are implementing outcome-based reimbursement approaches through national health technology assessment (HTA) and payer frameworks. It also examines the critical success factors for implementation, including robust real-world evidence generation, integrated healthcare data infrastructure, clearly defined outcome measures, stakeholder collaboration, legal and regulatory alignment, and transparent governance models. In addition, the resource addresses key operational challenges such as data collection complexity, administrative burden, outcomes measurement, reporting requirements, and confidentiality considerations. Looking ahead, the infosheet discusses how outcome-based agreements are expected to expand beyond oncology and rare diseases into broader therapeutic areas, supporting sustainable healthcare financing, improved patient access, and evidence-driven reimbursement decisions. Through its focus on market access, value demonstration, payer engagement, and real-world evidence, this resource provides valuable insights into the future of outcome-based healthcare and reimbursement innovation across Europe.",
"genre": "Info Sheet",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2026-03/europe-outcome-based-agreements.jpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2026-03-18",
"dateModified": "2026-03-18",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2026-03/outcome-based-agreements-europe.pdf",
"encodingFormat": "application/pdf"
}
}
]
}